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1. Introduction 
It  is  acknowledged  that  accurate  information  on  the  prevalence  of  drug  use  and 
especially  that  of  heroin  and  other  opiate  use  is  difficult  to  obtain.  Evidence  from 
national surveys and other sources indicate that the prevalence of heroin use in the 
general  population  is  relatively  low.  However,  most  of  the  widespread  drug-related 
health and social problems in EU countries are caused by the use of heroin and other 
opiates. Nevertheless, the substances causing health and social problems as well as 
the route of administration of these substances vary across Europe. In Sweden, for 
example, the drugs causing most of the problems are amphetamines, although like in 
Norway and Finland a new heroin wave is challenging the drug help system. On the 
other hand, the most common practice of using heroin in the UK is sniffing ("chasing 
the dragon") whereas in Germany, France and Italy intravenous use is the common 
way of administration. 
 
These  differences  in  substances  and  routes  of  administration  make  a  common 
definition of the target group rather difficult, since different substances and practices of 
use  are  related  to  different  health  problems.  Nevertheless,  comparisons  across 
countries  with  regard  to  the  extent  of drug use call for a common definition of the 
target  group,  the  use  of  equivalent  data  sources,  and  the  application  of  the  same 
methodology.  In  an  attempt  to  find  a  common  definition  in  spite  of  the  differences 
between  the  EU  countries  we  use  the  term  problem  drug  use  which  includes  all 
different forms of problems due to the use of opiates, cocaine, and amphetamines 
irrespective of the route of administration.  
 
Since most of the methods which are commonly used in EU countries to estimate the 
national prevalence of problem drug use are rather simple in terms of the mathematics 
required,  this  guide  will  focus  on  the  definition  of  the  target  group  and  data 
requirements  rather than on the statistical properties of the methods. 8 
 
2. Guide to the Guidelines 
What do I want to estimate?
See section 3
Have I defined
the target group?
See section 5
See section 4
Have I decided
upon the 
methods?
No
Yes
Yes
Have I defined
the data sources?
Go
Yes
No
No
Known Unknown See Introduction9 
3. Target Group 
The definition of the population targeted at by any prevalence estimation in the drug 
field is one of the most difficult tasks. The identification of substance users can only be 
derived from the known population, i.e., only when an individual comes into contact 
with the legal, medical or social system do we know that he or she is a user. Any 
definition of problematic drug use should therefore consider these three perspectives 
with their different interests, norms and values. In practice, however, the simultaneous 
consideration of these three perspectives is often not possible, may be e.g. due to the 
non-availability  of  data  bases  or  lacking  links  between  data  bases.  Thus,  the 
researcher is very often left with a pragmatic definition of the target group.  
 
Clinical System 
The International Classification of Diseases (ICD) and the Diagnostic and Statistical 
Manual  of  Mental  Disorders  (DSM)  give  clear  criteria  for  dependence  on  specific 
psychotropic substance groups, as well as for abuse.  Consequently, all other use can 
be assumed as unproblematic.  
 
DSM-IV disorders related to psychotropic substances include the following substance 
groups: 
•  Alcohol  
•  Opioids (e.g. heroin, morphine, codeine, methadone) 
•  Cocaine (e.g. cocaine, crack) 
•  Amphetamines  (e.g.  amphetamine,  dextroamphetamine,  methamphetamine, 
methylphenidate) 
•  Sedatives, hypnotics, anxiolytics (e.g. benzodiazepines, barbiturates) 
•  Hallucinogens (e.g. LSD, mescaline, ecstasy, psilocybin, DMT) 
•  Phencyclidine (e.g. PCP, ketamine) 
•  Inhalants 
•  Cannabis 
•  Nicotine 
•  Caffeine  
•  Multiple substance use is defined as use of substances of at least three substance 
groups in the last 12 months, without a clear preference for one main substance 
(except nicotine and caffeine) 
 
The  DSM-IV  differentiates  between  dependence  on  substances  and  abuse  of 
substances.  
Criteria for Substance Dependence 
A maladaptive pattern of substance use, leading to clinically significant impairment or 
distress, as manifested by three (or more) of the following, occurring at any time in the 
same 12-month period: 
(1) Tolerance, as defined by either of the following 
a)  a  need  for  markedly  increased  amounts  of  the  substance  to  achieve 
intoxication or desired effects 
b)  markedly  diminished  effect  with  continued  use  of  the  same  amount  of  the 
substance 
(2) withdrawal, as manifested by either of the following: 
a)  the characteristic withdrawal syndrome for the substance 10 
b)  the same (or a closely related) substance is taken to relieve or avoid withdrawal 
symptoms 
(3) the substance is often taken in larger amounts or over a longer period than was 
intended 
(4) there is a persistent desire or unsuccessful efforts to cut down or control substance 
use 
(5) a great deal of time is spent in activities necessary to obtain the substance (e.g., 
visiting multiple doctors or driving long distances), use the substance (e.g., chain-
smoking), or recover from its effects 
(6) important social, occupational, or recreational activities are given up or reduced 
because of substance use 
(7) the  substance  use  is  continued  despite  knowledge  of  having  a  persistent  or 
recurrent physical or psychological problem that is likely to have been caused or 
exacerbated  by  the  substance  (e.g.,  current  cocaine  use  despite  recognition  of 
cocaine-induced depression, or continued drinking despite recognition that an ulcer 
was made worse by alcohol consumption). 
 
Criteria for Substance Abuse 
A.  A maladaptive pattern of substance use leading to clinically significant impairment 
or distress, as manifested by one (or more) of the following, occurring within a 12-
month period: 
(1)  Recurrent substance use resulting in a failure to fulfil major role obligations at 
work, school, or home (e.g., repeated absences or poor work performance 
related  to  substance  use;  substance-related  absences,  suspensions,  or 
expulsions from school; neglect of children or household) 
(2)  Recurrent substance use in situations in which it is physically hazardous (e.g., 
driving an automobile or operating a machine when impaired by substance 
use) 
(3)  Recurrent  substance-related  legal  problems  (e.g.,  arrests  for  substance-
related disorderly conduct) 
(4)  Continued  substance  use  despite  having  persistent  or  recurrent  social  or 
interpersonal problems caused or exacerbated by the effects of the substance 
(e.g.,  arguments  with  spouse  about  consequences  of  intoxication,  physical 
fights) 
B.  The  symptoms  have  never  met  the  criteria  for  Substance  Dependence  for  this 
class of substance. 
 
The International Classification of Diseases (ICD-10) codes refer to the dependence 
syndrome as: „A cluster of behavioural, cognitive and physiological phenomena that 
develop after repeated substance use and that typically include a strong desire to take 
the  drug,  difficulties  in  controlling  its  use,  persisting  in  its  use  despite  harmful 
consequences, a higher priority given to drug use than other activities and obligations, 
increased  tolerance  and  sometimes  a  physical  withdrawal  state.  The  dependence 
syndrome  may  be  present  for  a  specific  psychoactive  substance,  for  a  class  of 
substances  or  for  a  wider  range  of  pharmacologically  different  psychoactive 
substances.“ Harmful use is defined as a consumption pattern, that leads to health 
problems  (e.g.,  a  physical  disorder  like  hepatitis  or  a  psychological  disorder  like 
depressive  episodes).  The  diagnosis  demands  an  actual  harm  of the psychological 
and/or physical health of the user. 
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These coding systems also account for the social system, as persons seeking help 
because of their substance use are very likely to fulfil the clinical criteria of ICD or DSM 
for at least abuse or harmful use. This can be quite different for the medical system. 
 
 
Medical System 
Substance users can be treated purely medically, because of a variety of reasons, like 
e.g. regular medical examination, pregnancy, dental state, non-fatal accidents under 
the influence of psychotropic substances, long-term effects of drug use like hepatitis or 
HIV, or they may try to utilise also prescribed drugs. In all these cases, it may not be 
clear,  whether  an  individual  fulfils  the  diagnostic  criteria,  as  no  diagnose  of  drug 
problems will be made. It may furthermore not be clear, whether practitioners know the 
status of their patients, or whether they are indeed „unproblematic drug users“. If not 
very  specific  information  of  such  a  data  source  can  be  obtained,  only  „use“  of 
psychotropic substances can be estimated. In a German study, it has been estimated 
that 44% of the practitioners treat patients that are regular hard drug users (Kirschner 
& Kunert, 1995). 
 
The data described above refers only to the health and social systems. Other data 
sources have never been meant to cover these medical and/or clinical definitions and 
must  therefore  be  based  on  different  definitions  (e.g.,  data  of  the  legal  system). 
However, the legal status of the substances varies between countries, which leads to 
difficulties in determining what a „problematic use“ may be according to different legal 
systems.  
 
 
Legal System 
An operational definition of problematic use may be that any person having come into 
contact with the legal system, i.e., having been registered in any police data base, has 
indeed a problem with his consumption pattern, and is therefore a problematic user. 
This  can  furthermore  be  differentiated  in  use  of  illicit  substances  or  use  of  licit 
substances, that were obtained illegally. 
 
 
Demands on a Definition 
Definitions of target group may combine a certain time period (e.g., a certain year), a 
specific  substance  group  (e.g.,  opioids,  amphetamines),  the  route  of  administration 
(e.g., intravenous injecting, smoking), frequency of use (e.g., experimental, occasional, 
habitual,  regular,  long  duration),  legal  status  (illicit,  licit),  and  clinical  diagnoses 
(dependence, abuse). As the utilised data bases, e.g. police data files or treatment 
monitoring systems, usually report data for a calendar year it is natural to use this time 
frame also for the prevalence estimation of problem drug use. Even when referring to 
the broadest possible target group, the „drug users“, any definition should include  
•  a time period  
•  an age group 
•  frequency of use 
•  and a definition of substances. 12 
 
From an epidemiological point of view, the definition should include an age group. As 
in the age group of the 15-34 year olds substance use is most spread, prevalence 
rates in this age group will be higher than in the age group of the 15-64 year olds. This 
may  furthermore  be  relevant,  if  “youth  drugs”  are  examined.  Studies  on  a  national 
scale  should  consider  if  and  how  differences  in  the  age  structure  of  the  general 
population distort comparisons. For comparisons of different national states prevalence 
rates per 1, 000 inhabitants of a certain age group should be calculated.  
 
Pragmatic Definition 
Not only does prevalence of substance use vary between countries, birth cohorts, and 
even gender, also route of administration differs greatly between substances, countries 
and  cohorts.  Even  if  route  of  administration  and  frequency  of  use  could  clearly  be 
related to a more or less hazardous consumption pattern, this information may not be 
directly  available.  Furthermore,  substances  are  used  in  quite  mixed,  often  chaotic 
patterns. Only very few opiate users do not use other drugs as well. On the other hand 
opiates, especially heroin, are the drugs, which cause most of the problems. If the 
pattern of drug use has to be labelled and categorised in a simple way, it can be done 
on  the  basis  of  the  drug  which  causes  the  highest  risk.  Complexity  can  be  further 
reduced by omitting the notion of primary and secondary drugs, and not accounting for 
polydrug use.  
 
A  pragmatic  definition  for  coding  according  to  this  concept  can  be  summarised  as 
follows: 
•  If a person uses heroin or other opiates he or she is always classified as opiate user 
regardless whether other drugs are taken as well. 
•  If no opiates are used then the person is a non-opiate user. He or she can then be 
classified as cocaine user (disregarding other drugs) or, if no cocaine is used, as 
amphetamine user.  
 
Although  not  all  groups  of  problem  drug  users  are  covered  by  this  definition  (e.g. 
problematic  users  of  cannabis),  they  are  not  included  in  the  target  group  as  the 
estimation methods described in these guidelines are in most cases not appropriate for 
these  groups.  For  example,  the  mortality  multiplier  method  can  only  be  applied  for 
groups of drug users who have a considerably high risk of dying because of their drug 
use.  This  applies  in  the  first  place  to  intravenous  opiate  users  (most  European 
countries) and amphetamine users (Sweden and Finland). 
 
This logic of categorising patterns of drug use is summarised in table 1. 
Table 1: Groups of problem drug users 
  Groups  Opiates  Cocaine  Ampheta-
mines 
Opiate users  Problem Opiate 
user 
Yes  Yes/No  Yes/No 
Non-opiate users  Problem Cocaine 
user 
No  Yes  Yes/No 
  Problem 
Amphetamine user 
No  No  Yes 
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As  mentioned  in  the  section  “Demands  on  a  Definition”  above  the  definition  of  the 
target group should not be restricted to the substances but should also include a time 
period, an age group as well as consumption patterns. Clinical diagnoses would be 
preferred but are not available from most of the data bases. As time period a one year 
period is widely accepted to define a current status. Since many data bases do not 
include age, the age range of the target group should be wide enough to cover the 
majority of problem drug users. On the other hand reference to the total population 
does not make sense because different demographic structures in different countries 
would make cross-national comparisons unreliable. Within the EMCDDA project the 
age  range  15-54  was  chosen.  To  increase  comparability  with  other  indicators,  the 
more often used age range 15-64 should be selected. 
 
In summary, we arrived at the following: 
An operational definition of a target group would be 
•  Intravenous  drug  use  (IDU)  or  long  duration/regular  use  of  opiates,  cocaine  or 
amphetamines,  
•  During a one-year period,  
•  In the age group 15-64.  
 
 
Literature 
Kirschner, W. & Kunert, M. (1995). Umfang und Struktur von i.v. Drogenabhängigen in 
Deutschland. Anonymes Monitoring in den Praxen niedergelassener Ärzte. Empirie 
der Gesundheitswissenschaften, Bd. 1. München: Profil Verlag. 
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4. Data Sources 
Clinical, Medical, and Social System 
The clinical, medical and social systems collect the most detailed information on drug 
users. A drug user can come into contact with: 
•  Drug  treatment  agencies  (inpatient  versus  outpatient,  specialised  on  drug  care 
versus  general  treatment  agencies;  e.g.,  drug  counselling  centres,  general 
counselling centres, psychiatric hospitals, and specialised hospitals),  
•  Low  threshold  agencies  (e.g.,  needle  and  syringe-exchange  schemes,  drop-in 
centres), 
•  Substitution services (dependent on the regulation in each country these may be 
general practitioners, substitution ambulances, hospitals, treatment agencies), 
•  General practitioners (medical reasons), 
•  Emergency ambulances (mobile or stationary), 
•  HIV/hepatitis related services,  
•  Clinical psychologists,  
•  Psychiatrists. 
 
Problems associated with these data sources are: 
•  In general, treatment monitoring systems do not cover all treatment facilities of a 
country. To utilise treatment data for prevalence estimation an extrapolation of the 
treatment  centres  included  in  the  monitoring  system  to  all  treatment  centres  is 
necessary.  For  an  estimate  of  the  coverage  rate,  the  exact  number  of  centres 
involved  in  treatment  of  drug  addicts  must  be  known.  Besides,  the  treatment 
facilities represented in the treatment monitoring system may differ from others, 
e.g.,  with  respect  to  the  average  number  of  treated  drug  users.  Note,  that  the 
coverage  rate  should  not  be  confused  with  the  in-treatment  rate  which  is  the 
proportion of problem drug users in treatment. 
•  Agencies usually collect their data for themselves, and in rather few countries a 
general treatment monitoring system covering most of the treatment centres has 
been established. Furthermore, double counting cannot be excluded, as many drug 
users will come into contact with a variety of treatment facilities. Due to privacy 
laws utilising unique personal identifiers to prevent double counting is impossible in 
some European countries. 
•  Drug users in urban areas have more options for receiving treatment in comparison 
to rural areas. On the other hand, the latency period between onset of drug use 
and treatment admission seems to be shorter in less urbanised areas which might 
be related to stronger social cohesion in rural areas. Therefore, the probability of 
coming into contact with treatment facilities is nationwide not constant. 
•  Some  treatment  agencies  are  interrelated  and  send  patients  to  certain  other 
centres.  
•  The capacity of facilities is limited, drug users may be set on waiting lists. They 
might break off contact again, before any data can be collated, or they may leave 
incomplete, unreliable or even wrong data. There exists a population of drug users 
not covered by the drug-related social and medical system.  
•  It is very likely, that every drug user comes into contact with a general practitioner, 
but this rather seldom utilised data base has manifold problems. It is not clear, how 
many drug users will be recognised while visiting a doctor for medical reasons not 16 
obviously related to drug-use. Furthermore, in case of a non-fatal accident under 
influence of psychotropic substances it is almost impossible to distinguish between 
regular, occasional or experimental users.  
 
Legal System 
Data of drug users can be found in registers 
•  on convictions because of offences against laws on consumption, possession or 
supply of illegal drugs, 
•  on  convictions  because  of  secondary  crimes,  i.e.  offences  associated  with  the 
obtaining of drugs (theft, shoplifting, prostitution, forgery), 
•  on convictions because of offences under the influence of psychotropic substances 
(e.g. driving, violence), 
•  on detainees in connection with the above mentioned categories, 
•  on mortality (e.g., all-cause deaths of registered drug users, drug-related deaths). 
 
Problems associated with these data sources are: 
•  It is difficult to distinguish between consumers and dealers of drugs. Frequency of 
drug use cannot easily be obtained, in order to separate regular from experimental 
users. Police recordings do usually not distinguish between minor experimentation 
with drugs, severe drug problems, mere trade without consumption, and long or 
regular users.  
•  It  is  not  clear  if  utilising  data  bases  on  offences  tends  to  underestimate  or  to  
overestimate  problem  drug  use  prevalence  as  an  offence can be committed by 
several  offenders  and  on  the  other  hand  one  individual  can  commit  several 
offences. 
•  Secondary crimes may not be registered at all, and dependent on the drug policy of 
a country no special attention may be paid on detecting them as connected to drug 
use.  
 
Mortality Data 
Most  European  countries  have  national  and/or  regional  mortality  registers  where 
deaths are coded using the International Classification of Diseases (ICD). However the 
definition  of  drug-related  deaths  and/or  the  registration  strategies  may  vary  across 
countries. While in the Netherlands and in Italy only deaths due to an overdose are 
registered as drug-related deaths in other countries a wider definition is adopted. In 
Germany a drug-related death includes deaths “following overdose, as a result of a 
long-term abuse, suicide resulting from despair about the circumstances of life or the 
effects of withdrawal symptoms, and fatal accidents under the influence of drugs”. In 
Denmark “deaths caused by accident or suicide due to: misuse of illegal drugs; misuse 
of other drugs if the deceased was a known drug addict; or misuse of intoxicating but 
not illegal drugs” are registered as drug-related deaths (EMCDDA, 1997). The applied 
definition and/or the registration strategies may vary to a great extent not only between 
different European countries, but also within one country between regions or urban in 
contrast to rural areas. 
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An  overdose  may  be  accidental,  intentional  or  undetermined.  Accidental  overdoses 
include deaths after periods of abstinence when the tolerance has changed, as well as 
overdoses  while  using  methadone  or  naltrexon.  An  overdose  can  also  be  held 
responsible when in fact the substance is contaminated. Regular as well as occasional 
users can die of an overdose. This death may be coded as a drug-related death or it 
may be coded alternatively as due to respiratory failure. The latter code will not be 
detected as a drug-related cause, if the deceased has not been known as a drug user 
before. Therefore, the number of deaths from any regional or national register will very 
likely be a lower limit of the actual figure.  
 
Further  types  of  drug-related  deaths  are  fatal  accidents  under  the  influence  of 
psychotropic substances (excluding alcohol) and suicides related to dependence on 
drugs. Deaths resulting from long-term abuse of psychotropic substances can be part 
of the definition as well as deaths due to violence under the influence of psychotropic 
substances. It is important to understand how the registration operates, who completes 
death certificates (pathologist or medical practitioner). Valuable information can also 
be  gained  from  customary  practices  of  coding  primary  and  secondary  causes  of 
fatalities associated with drug overdoses. If it is not possible to establish the number of 
all-cause deaths, some subsets may be more clearly defined, e.g., drug overdoses. 
 
Links Between Data Bases 
When data bases are linked, definitions should be comparable between sources along 
several dimensions: 
•  Substances used 
•  Time period 
•  Age range 
•  Frequency of use 
•  Route of administration 
•  Geographical area 
 
In most cases, data sources may not be comparable along all characteristics listed 
above,  some  may  not  even  be  explicitly  recorded  (e.g.,  route  of  administration,  or 
frequency of use may not be recorded in a police register). For some properties of the 
selected data, it is possible to collate the data or clean them afterwards according to 
given definitions (e.g., age range). If this is not possible, at least a minimum definition 
covering  substances  used,  time  period  and  age  group  should  be  met.  Data 
requirements for single methods are considered in the specific chapters. 
 
Literature 
EMCDDA (1997). Annual Report of the State of the Drugs Problem in the European 
Union. Lisbon: EMCDDA. 18 
5. Methods 
5.1.  The Multiplier Method 
In the context of problem drug use the total population of drug users T is unknown 
(partly  hidden  population).  Given  a  sample  of  size  B  of  the  population  in  question 
(benchmark)  and  the  probability  c  for  someone  of  this  unknown  population  to  be 
member of the sample, the total population T can be estimated from 
  T = B / c 
B:  the number of identified problem drug users (sample or benchmark) 
  c:   a parameter giving the probability of a problem drug user (unknown 
target population) to be member of the identified sample B 
Note that dividing by c is equivalent to multiplying by 1/c (multiplier) (table 1). 
 
The number of identified problem drug users (benchmark) is usually provided by or 
calculated from routine sources, e.g. by treatment centres, monitoring systems, police,  
drug death and/or HIV/AIDS registers. Generally, the value of the benchmark can be 
taken directly from a register or can be extrapolated by simply multiplying the given 
data  with  an  appropriate  factor.  For  instance,  multiplying  the  number  of  treatment 
centres covered by a monitoring system with the coverage rate yields the benchmark 
for the treatment multiplier method.  
 
The value for c must be estimated using independent external information and should 
be updated from time to time. This requires extensive research as expert ratings may 
be misleading. Appropriate estimation methods include capture-recapture (see chapter 
5.2) or nomination techniques. Nomination techniques refer to sampling methods that 
collect  data  not  just  from  the  respondent  but  also  from  persons  nominated  by  the 
respondent (Taylor, 1997; Korf, 1997). Sometimes, results of other projects can be 
used  as well. For example, one spin-off of a project on drug-related deaths in five 
South German cities was an estimate of the in-treatment rate of opiate dependents 
(Augustin & Kraus, 2004) 
 
Usually,  multipliers  are  estimated  from  small-scale  studies.  A  generalisation  of  this 
local estimate to the whole country may be problematic as e.g. the probability of an 
opiate user to get into contact with the police may vary over regions and cities due to 
law enforcement activities. Therefore it is recommended to use mean estimates from 
at least 3 to 4 different areas including cities and rural municipalities. 
 
Benchmark and multiplier must fit each other and the target group. If e.g. the number 
of drug-related deaths is used to estimate the number of problem opiate users both 
benchmark (drug-related deaths) and multiplier (mortality rate) must be based on the 
same  definition  of  drug-related  deaths  (overdoses  vs.  all-cause  deaths).  For  the 
estimation of the prevalence of problem cocaine use based on treatment data an in-
treatment rate derived from a sample of opiate dependents may be misleading. 
Table 1: Data and sources for the multiplier method 19 
Parameter  Data  Source of 
information 
Section 
B  Number  of  problem  drug  users  who  underwent 
treatment in a given year 
Treatment 
centres, 
Monitoring 
systems 
5.1.1 
c  Probability for a problem drug user to be treated (in-
treatment rate) 
   
       
B  Number of registered problem drug users in a given 
year 
Police  5.1.2 
c  Probability for a problem drug user to be registered by 
the police in that year 
   
       
B  Number of problem drug users registered by the police 
for  the  first  time  (over  a  period  reflecting  mean 
duration of addiction) 
Police  5.1.3 
c  Proportion of drug-related deaths that have previously 
been registered by the police as problem drug users 
(also over the same period) 
   
       
B  Number of drug-related deaths in a given year  Mortality 
register, 
Police 
5.1.4 
c  Probability of death among problem drug users in the 
same year 
   
       
B  Number of HIV infected drug injectors in a given year  HIV/AIDS 
register  
5.1.5 
c  Prevalence of HIV infections among drug injectors in 
the same year 
   
B=benchmark, c=multiplier 
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5.1.1  Multiplier Method Using Treatment Data  
The  number  of  problematic  drug  users  registered  in  treatment-centres  serves  as 
benchmark. If the treatment monitoring system does not cover all treatment centres an 
estimate of the treatment coverage-rate should be used to extrapolate to all treatment 
centres. The in-treatment-rate of problematic drug users has to be estimated, e.g. by 
applying snowball-sampling and other nomination-techniques as described in Taylor 
(1997). 
 
 
Example: The Netherlands 
The  benchmark  is  the  total  number  of  opiate  users  (including  poly-drug  users)  in 
outpatient  treatment  centres  registered  in  the  Dutch  National  Alcohol  and  Drugs 
Information  System  (LADIS)  which  has  a  comparatively  high  coverage.  Only  2,777 
methadone  clients  of  the  Municipal  Health  System  in  Amsterdam  and  1,334 
methadone clients of the Symbion Foundation in Rotterdam are not included in LADIS. 
Adding those clients to the 14,748 problematic opiate users registered in LADIS yields 
a total of 18,859 problematic opiate users in 1996. Any presumable overlap between 
the clients in LADIS and those added from Rotterdam and Amsterdam could not be 
excluded.  
 
The multiplier was based on research in two regions, namely in Amsterdam and in 
Rotterdam (Buster & Reurs, 1997; Toet, 1995). In both regions the in-treatment rate 
estimate was 0.70. Because of a lack of information about in-treatment rates outside 
Amsterdam and Rotterdam a range of 0.65-0.75 seems to be reasonable. Given that 
the care agencies reached on average 65% of the total number of users nationally, 
there are 18,859/0.65=29,014 estimated problem opiate users in the Netherlands: If 
75%  is  taken  as  an  average  percentage  nationally,  there  are  18,859/0.75=25,145 
estimated problem opiate users in the Netherlands (Toet, 1999). 
 
 
Data Demands 
The treatment monitoring system should not only provide figures of drug users seeking 
treatment  categorised  by  main substance groups, but should also be able to avoid 
double  counting.  Furthermore,  it  is  important  to  consider  the  coverage  rate  of  the 
monitoring system.  
 
An estimate of the treatment coverage rate cannot be obtained easily as treatment 
centres can include inpatient and outpatient treatment facilities, e.g., specialised drug 
care centres, low- and high threshold agencies, general psychiatric hospitals, doctors´ 
surgeries and substitution programmes as well as smaller substitution facilities. Thus 
simply extrapolating the treatment centres included in the monitoring system to all the 
treatment centres may give a wrong picture. In Germany, for instance, extrapolating 
the  number  of  treatment  centres  yields  a  much  smaller  coverage  rate  than 
extrapolating the number of staff of the treatment centres as bigger treatment centres 
are more likely to be included in the treatment monitoring system. Besides, drug users 
can be treated because of a variety of other reasons connected to problematic drug 
use, like e.g., hepatitis. It is necessary to define the extent of treatment that will be 
taken into account for the treatment monitoring system: shall only treatment because 
of dependence and abuse be taken into account or shall also data on other health 21 
problems  connected  with  problem  drug  use  be  utilised?  How  can  the  problem  of 
double  counting  be  minimised,  if  e.g.  country-specific  laws  on  privacy  make  an 
individual identifier impossible?  
 
The question of specific target groups should be considered carefully when collecting 
data. On the basis of the following characteristics any target group could be estimated: 
•  Differentiation between polydrug and monodrug use. 
•  Categorisation  of  main  problem  drug  according  to  a  clearly  defined  hierarchical 
scheme. 
•  Differentiation between dependence and abuse or known frequency and duration 
of use. 
 
The main problem of this method of estimation is the „in-treatment-rate“, i.e. the rate of 
problem drug users seeking help in a given year. The calculation of this rate is closely 
connected to the definition of treatment facilities utilised. A very narrow definition of the 
in-treatment-rate would cover only persons seeking help in order to give up drug use 
and would therefore consider only inpatient and outpatient treatment facilities. In order 
to include also drug users who do not intend to quit, low threshold-agencies should be 
taken into account as well. The broadest possible definition of the in-treatment-rate 
would include also general practitioners. Of course, the definition of the in-treatment 
rate  must  suit  to  the  definition  of  the  benchmark.  The  broadest  definition  must  be 
chosen if and only if the benchmark includes general practitioners. On the other hand 
side, if the benchmark includes only inpatient and outpatient treatment facilities the 
narrowest definition of the in-treatment rate must be used. There is no relationship 
between the narrowness of the definition and the estimate: An estimate based on the 
narrowest  definition  may  be  higher  or  lower  than  an  estimate  based  on  a  wider 
definition.  
 
 
Limitations 
Dependent  on  the  national  monitoring  system,  not  all  treatment  facilities  may  be 
covered,  or  not  even  the  exact  number  of  treatment  facilities  dealing  with  drug 
problems may be known. If a coverage rate is known, the estimate can be improved. 
Users not in contact with the treatment system are not taken into account. The figures 
obtained with this method have to be considered as lower bounds.  
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5.1.2  Police Multiplier Method  
In analogy to the extrapolation of treatment data (chapter 5.1.1), the number of drug 
users  registered  by  the  police  in  a  given  year  can  be  extrapolated.  The  number  of 
registered problematic drug users in a given time period is taken as a benchmark. If 
there is no nationwide police registration system but only regional registers an estimate 
of the coverage-rate should be used to extrapolate to the whole country. To account for 
the hidden population, this figure is divided by the estimated proportion of drug users that 
have come into contact with the police. For that estimate a small scale study is needed, 
that  will  very  likely  be  conducted  on  a  regional  basis.  Nomination  techniques  as 
described in Taylor (1997) and Korf (1997) or capture-recapture methods (see chapter 
5.2) may be used. 
 
 
Example: France 
In  France  8,720  individuals  were  arrested  for  using  or  using  and  selling  heroin  or 
cocaine in France in 1999. The multiplier was estimated by combining two different 
results:  the  prevalence  of  opiate  or  cocaine  users  for  Lens,  Marseille  or  Toulouse, 
provided by the capture-recapture method (10,117 individuals), and individuals living in 
Lens, Marseille or Toulouse who were arrested for heroin or cocaine use in 1999 (590 
individuals). The result is: 590/10,117  = 0.058. 
Altogether, the 1999 national prevalence estimate of problem opiate or cocaine use is 
T = B / c = 8,720 / 0.058 = 150 000. 
 
 
Data Demands 
The  utilised  data  bases  should  be  person-based,  distinguish  between  dealers  and 
consumers of drugs and register the offenders by type of drug. If only data bases on 
offences but not on offenders are available (i.e. event-based instead of person-based) 
it is even not clear if prevalence is under-estimated or over-estimated as an offence 
can  be  committed  by  several  offenders  and  on  the  other  hand  one  individual  can 
commit several offences.  
 
 
Limitations 
For estimating the proportion of problematic opiate users that have come into contact 
with the police, a small-scale study is needed. This study will probably be conducted on 
a regional basis, for example, in a larger city. A generalisation of this local estimate to 
the whole country may be problematic. The probability of an opiate user to get into 
contact  with  the  police  may  vary  over  regions  and  cities  due  to  law  enforcement 
activities.  This  makes  estimates  rather  unreliable.  If  law  enforcement  bodies  in  the 
examined  region  are  more  efficient  than  on  average,  this  will  result  in  an 
underestimation and vice versa. Therefore it is recommended to include at least 3 to 4 
different cities and a rural area town at once in the small-scale study.  
 
Techniques that may be used to estimate the multiplier are, for example, nomination 
techniques,  which  are  described  in  Taylor  (1997)  and  Korf  (1997)  or  the  capture-
recapture method as described in chapter 5.2. 24 
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5.1.3  Police/Deaths Multiplier Method 
This multiplier method is based on two data sources, namely the data base of first 
registered opiate users and the data base of drug-related deaths. As according to the 
literature (Robins 1979; Bschor 1987; Marks 1990) the estimated mean duration of 
dependence amounts to ten years, the number of first-time registered opiate users in 
the previous ten years is taken as the benchmark. The correction term assumed to 
reflect the extent of the unknown cases is the ratio of the total number of drug-related 
deaths to the number of those deceased previously registered by the police as opiate 
users. Again, this comparison is made over a ten-year period. It is assumed that the 
ratio of the total number of problematic drug users to the number of those cases that 
have been registered by the police (over a ten-year period) is equal to the ratio of the 
total number of drug-related deaths to those that have previously been registered by 
the police as problematic drug users (also over a ten-year period). 
 
In summary, the following calculations are applied:  
T  Estimated total of problematic drug users 
B  Number of first-time registered drug users in the past ten years 
c  Dt/Dn,  ratio  of  the  number  of  drug-related  deaths  and  the  number  of  drug-
related deaths previously known by the police as drug users, 
where 
Dt  Number of drug-related deaths in the past ten years 
Dn  Number  of  drug-related  deaths  in  the  past  ten  years  having  been 
registered as drug users before 
⇒  T = B * c 
 
The proportion of all previously known users among drug-related deaths varies over 
time. Thus, using just one multiplier might be problematic. Therefore, as a variant this 
proportion is calculated for each of the past ten years and multiplied with the number of 
first-time  registered  opiate  users  in  that  year.  To  arrive  at  an  estimate  of  the  total 
prevalence the estimated incidence is again cumulated over ten years (assuming a 
duration of problematic opiate use of ten years). 
 
 
Example: Germany 
In Germany, law enforcement data collected on the number of drug offenders include 
information on the substance consumed by an individual. However, drug offenders are 
only included in the data the first time they are charged and no distinction is made 
between  drug-addicts  and  episodic  users.  Additionally,  the  regular  comparison  of 
national drug-related deaths and the registered drug user data allows to keep a record 
of previously unknown individuals. To estimate the number of first registered hard drug 
users the number of cases known by the police over the last 10 years are counted. 
This ten-year period reflects the mean duration of an individual’s drug use.  
The  number  of  heroin  users  registered  by  the  police  for  the  first  time  serves  as  a 
benchmark. According to the literature (Robins, 1979; Bschor, 1987; Marks, 1990) the 
estimated mean duration of heroin addiction is ten years. To estimate prevalence, the 26 
number of first-time offenders against drug laws in the previous ten years are summed 
up. 
 
The correction term assuming to reflect the extent of the dark-field is the ratio of the 
total  number  of  drug-related  deaths  to  the  number  of  these  deceased  individuals 
previously registered by the police as hard drug users. Again, this comparison is made 
over a ten-year period. As the proportion of all known users among drug related deaths 
varies over time, and using just one multiplier might be problematic, a variant of this 
method was calculated: In a first step the required proportion is calculated for each 
year between 1986 and 1995. This information, however, has only been available since 
1992. For the years 1986 and 1991 this proportion varies between 30% and 55%. To 
get an estimate of the total prevalence the estimated incidence is again cumulated 
over ten years (assuming a duration of problematic drug use of ten years). Note, that 
the  statistics  on  drug-related  deaths  also  include  deaths  of  non-opiate  users.  It  is, 
however, reasonable to assume that most of the registered drug-related deaths are 
heroin-related in Germany as deaths due to suicides, fatal accidents and long-term use 
of other substances than opiates are often not recognised as drug-related death. In 
fact, in 1995 nearly two thirds of the drug-related deaths were due to heroin overdoses. 
It is estimated that in 1995 altogether more than 70% of the registered drug-related 
deaths were related to heroin use (Bühringer et al., 1997). In Table 2 the calculations 
for the estimate are summarised (Bühringer et al., 1997; EMCDDA, 1997a). 
 
Table 2: Extrapolation from police data for Germany  
Year  N of offenders first 
registered by police 
Correction term  Year-specific 
estimate 
  B  c=Dt/Dn  T 
1986-1991  33,677  1.43 – 2.22  48,158 – 74,763 
1992  10,452  2.23  23,308 
1993  8,384  1.92  16,097 
1994  8,501  2.40  20,402 
1995  6,970  2.57  17,913 
Total      125,878 – 152,483 
 
 
Data Demands 
The two registers utilised for the estimation method are the data base of registered 
opiate users by the police and the data base of drug-related death. 
 
Data of the first data base have some limitations that cannot easily be overcome: 
•  Problems with a clear definition of target groups: In some countries it is often not 
possible to decide whether a person registered for the first time as an offender is 
consuming drugs himself or if he is trafficking drugs. Furthermore, if a person is 
registered  as  an  user,  it  is  not  possible  to  distinguish  between  occasional  and 
regular user, i.e., no information is available whether he or she is a problematic 
user or not. In some cases misclassifications of the main substance are possible 
and poly drug use is not accounted for. 
•  Because of privacy laws, cases have to be deleted from the police data so that 
double counting cannot be fully excluded.  27 
•  Data may be biased because of delays in data entry and variations in recording of 
data across police services. 
 
National register on drug-related deaths: 
These  problems  have  already  been  considered  in  chapter  4  on  data  sources.  The 
greatest problem may be to establish a definition of drug-related deaths that covers the 
registration praxis of the register. Attention should be paid on regional differences in 
the  registration  and/or  definition,  e.g.,  differences  between  urban  and  rural  areas, 
where it might be more likely to “cover” a drug-related death in order to protect the 
privacy of a family. Valuable information can be gained from customary practices of 
coding  primary  and  secondary  causes  of  fatalities  associated  with  drug  overdoses. 
Where it is not possible to establish the number of all-cause deaths, a subset may be 
more clearly defined, e.g., drug overdoses. 
 
The link between the two data bases is of importance in identifying deceased that have 
been registered as drug users before. As no established figures on the duration of 
drug  use  are  available  at  the  moment,  the  time  period  over  which  the  calculations 
should be summarised are somewhat unclear.  
 
 
Limitations 
Usually, drug-related deaths are based on different definitions in different countries. In 
Germany, for instance, the statistics on drug related deaths do not only cover deaths 
due  to  an  overdose,  but  also  suicides,  fatal  accidents  under  the  influence  of 
psychotropic  substances,  and  deaths  resulting  from  long-term  abuse.  In  Italy, 
offenders first registered by the police include all types of users (first user, user, addict, 
etc.),  and  all  types  of  substances  used  (cannabis,  ecstasy,  cocaine,  heroine,  etc.). 
Different  offenders  against  drug  laws  may  also  be  available.  In  Germany  only  the 
offence „possession for personal use“ is used for the estimation of the benchmark. In 
Italy there are three paragraphs, 72, 74 and 75, of which the last one is ‘possession for 
personal use’. In France four categories exist, two refer to ‘simple use’ and ‘use and 
resell’  and  two  to  trafficking  definitions.  The  first  two  comprise  about  70%  of  all 
offences.  In  the  Netherlands  not  possession  of  drugs  is  used  but  drug  users  are 
identified from other offences (burglary etc.) as possession is registered very rarely.  
 
Drug-related deaths are very likely due to intravenous opiate use, which is in most 
cases exclusively use of heroin, or polydrug use. Fatal accidents under influence of 
psychotropic substances might be very difficult to separate for substance groups, and 
the same can be said for suicides.  
 
On the other hand, opiate users in contact with the police may to some extent also 
include other drug users, e.g. cocaine users. In most cases, however, it will be very 
difficult to decide whether the registered first offender is a cocaine or cannabis user if 
caught with cocaine or cannabis, or if he will also take opiates at other times, as it is 
very unlikely that a drug user will state freely his consume behaviour at the police-
station. Therefore, the population covered by a police register will mostly consist of 
opiate users, but can also include users of other psychotropic substances. 
  28 
In summary, because of the problems of separating deaths for substance groups and 
of categorising first offenders in terms of substances prevalence estimates of problem 
use for certain substances may be biassed.  
 
The  most  crucial  point  is  the  estimate  of  the  mean  duration  of  problem  drug  use. 
Obviously, the end of problematic drug use cannot be observed since a client who has 
finally terminated his drug use will never appear in the drug treatment system again. 
On the other hand, even if it is known from a follow-up study that somebody does no 
longer take drugs it is not clear if he later will take up drug use again. Though there are 
some  estimates  for  the  mean  duration  of  dependence  or  problem  drug  use  no 
estimation procedure can be recommended here as no estimation procedure is able to 
handle the above mentioned problems and the figure of ten years can thus not be 
validated. All the methods used to estimate the mean duration of problem drug use are 
based on assumptions which can not be corroborated. In France, e.g. where mean 
duration of problem heroin use is estimated at 8 years it is assumed that the number of 
forthcoming  treatments  of  an  individual  equals  the  number  of  up  to  now  observed 
treatments.  The  mean  duration  of  problem  heroin  use  is  estimated  as  the  time 
between  onset  of  problem  drug  use  and  first  treatment  plus  twice  the  up  to  now 
observed treatments multiplied with the average time span between two treatments 
(Costes, 1999). The effects of handling right-censoring by simply doubling observed 
figures  are,  however,  not  clear.  For  this  method  two  assumptions  are  necessary, 
namely that the time of the survey is independent of the observed process (i.e., the 
number of treatments) and that the observed process does not change in time (e.g., 
due to legal changes the number of treatments per client will be restricted in the future) 
(Preisendörfer  &  Wallaschek,  1987).  This  method  provided  very  bad  results  in  an 
empirical comparison with the results of a panel analysis in an attempt to estimate the 
duration of being employed in a certain company (Preisendörfer & Wallaschek, 1987). 
This finding is not surprising since in this panel study not all observations are right-
censored and therefore more information is provided. But even with a panel study the 
problems mentioned above will not disappear. A different estimation procedure is given 
in Marks (1990). He claims that each year 5% of the addicts gave up their drug use 
and that therefore within 10 years one half of the addicts terminated drug use. This 
figure is, however, rather an estimate of the median length of problem opiate use than 
of  the  mean  length.  Apart  from  difficulties  in  validating  the  termination  rate  a 
termination rate of 5% each year does not yield 50% in ten years as population size is 
decreasing from year to year and 5% of a smaller population is less than 5% of the 
original population. Here further research is needed. Even if it seems to be impossible 
to develop reasonable estimation procedures small scale studies could give hints if the 
figures on mean length of problem drug use are plausible. 
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5.1.4  Multiplier Method Using Mortality Data 
This estimation method is based on the total of drug-related deaths and the mortality rate 
of problem drug users. To get an estimate for the past year prevalence of problem drug 
use, the total of drug-related deaths is divided by the mortality rate.  
 
 
Example: Germany 
Each year about 1600 drug-related deaths are registered in all of Germany. As studies 
on emergency room episodes and others indicate an annual mortality rate of 1.5-2% 
for drug addicts in Germany, this can be used as multiplier for the calculation of the 
total number of drug addicts. As mortality is mostly linked to intravenous drug use, 
changing  patterns  of  drug  use  can  influence  this  estimation    in  a  critical  way.  The 
sharp increase in methadone substitution programmes in Germany for example seems 
to reduce mortality for drug users - which is one of the intentions of the programme. 
This  might  effect  the  validity  of  this  type  of  estimation.  The  estimation  is  80,000  – 
112,000 for this method (Kraus, Augustin & Simon, 1999). 
 
 
Data Demands 
The mortality rate being highly specific and clearly referring to a neatly defined target 
group may vary a great deal over time. For example, impurities of certain substances 
in an area may be responsible for substantial changes in proportions of drug-related 
deaths  as  well  as  the  influence  of  substitution  programmes,  needle  exchange 
programmes and other harm reduction approaches. In areas where annual data are 
available it may be advisable to use a moving average over several years (Frischer, 
1997), i.e., to replace the mortality rate of a certain year by the average mortality rate 
of  that  year  and  one  or  two  adjacent  years.  Instead  of  the  1996  mortality  rate the 
average of the 1995 mortality rate, the 1996 mortality rate and the 1997 mortality rate 
is applied to the 1996 drug - related deaths data. Moving averages smooth the time 
series of mortality rates.  
 
 
Limitations  
Due  to  changing  circumstances  like  improving  treatment  facilities  for  AIDS,  the 
emergence of new drugs or the introduction of methadone programmes, mortality rates 
are not constant and have to be re-estimated periodically. How these circumstances 
affect mortality rates is, however, not clear. Studies in several countries on the impact 
of HIV on non-AIDS-related mortality and on the impact of methadone on mortality 
report very different results (Frischer, 1997). The existing mortality rate estimates are 
almost exclusively based on studies on drug users in treatment (Davoli, 1997, Frischer, 
1997). The mortality rate of non-treated drug users is probably different. Moreover, 
mortality rates normally are estimated only for certain types of drug users or types of 
drugs, and contain all-cause deaths. It is important to recall that the registers on drug-
related deaths may not contain all deaths of drug addicts (usually overdose). Thus, the 
benchmark of the mortality multiplier method is obviously too low. 
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As  mortality  rates  are  normally  rather low small changes in the estimated mortality 
rates will have a big influence on the prevalence estimate. If e.g. the mortality rate is 
estimated as 2% instead of 4% the prevalence estimate will be doubled.  
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5.1.5  Multiplier Method Using HIV/AIDS Data 
This estimation method is based on the number of HIV/AIDS infected IDUs and the 
proportion of HIV/AIDS among IDUs. Dividing the number of HIV/AIDS infected IDUs 
by  an  estimate  of  the  proportion  of  AIDS  among  IDUs  (P(AIDS|IDU))  yields  an 
estimate of the IDU prevalence N(IDU).  
 
 
Example: Belgium 
In  Belgium,  the  number  of  HIV  infected  IDUs  (benchmark)  was  estimated  by 
multiplying the number of alive HIV cases by an estimate for the prevalence of IDU 
among  HIV-positives.  In  1997,  7,819  HIV  and  AIDS  cases  aged  15-64  years  were 
registered  in  two  integrated  databases  at  the  Scientific  Institute  of  Public  Health in 
Brussels. From the 4,505 individuals with known IDU status in these databases 360 
were injecting drugs, yielding a prevalence rate of IDU among HIV-positives of 8.00%. 
In Summary, the benchmark was estimated at 7,819*8.0=626 HIV infected IDUs. 
 
In a survey conducted in Flanders (1996-1997), 186 drug users reported to have been 
tested for HIV and 5 of them, i.e. 2.7% of the sample, reported to be HIV seropositive. 
During this survey, a HIV blood test was also performed on all IDUs (n=225) but no 
new case was detected, giving thus a more accurate estimate of the multiplier of 2.2%. 
 
Altogether, the total of lifetime IDU cases is estimated at 626/2.2=28,400. 
 
Data Demands 
This method requires the total of HIV/AIDS-positive IDUs (benchmark) and an estimate 
of the prevalence of HIV/AIDS among IDUs. In many countries, only AIDS cases may 
be  registered.  Estimating  lifetime  IDU  prevalence  based  on  registered  AIDS  cases 
among IDUs and on an estimate of the prevalence rate of AIDS cases among IDUs is, 
however, not recommended. As the multiplier will be very small, the result depends 
heavily on the multiplier. Small changes in the multiplier will result in big changes in the 
IDU prevalence estimate. Also employing the back-calculation method (Downs et al., 
1997; Rossi & Ravà, 1999) to estimate the prevalence of HIV/AIDS cases from the 
AIDS  cases  is  no  longer  recommended.  New  developments  in  AIDS  therapies 
changed parameters used in the back-calculation method as e.g. latency time.  
 
 
Limitations  
•  The  AIDS  epidemic  among  IDUs  has  to  be  comparable  large  to  lessen  the 
influence of a wrong estimate for the denominator. If  the denominator is estimated 
as 2% instead of 4% the IDU prevalence estimate will be doubled. If, however, the 
“true” denominator is 15% and it is estimated to be 13% the prevalence estimate is 
multiplied only by the factor 1.15. 
•  The  estimate  of  the  denominator  is  normally  derived  from  a  local  sample  of  a 
subgroup.  This  subgroup  should  be  reasonably  representative  for  the  IDU 
population in a country. Samples, e.g., from anonymous AIDS testing facilities, give 
biased estimates as those testing facilities particularly attract clients which expect 
to  be  infected.  Besides,  in  some  countries  local  estimates  of  P(AIDS|IDU)  or 33 
P(AIDS∪HIV|IDU) differ strongly from region to region but a plausible range might 
be used. 
•  This method provides rather an estimate of IDU lifetime prevalence as HIV infected 
or AIDS affected individuals may exit from the IDU population.  
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5.2.  Capture-Recapture Method 
Statistical Background 
The capture-recapture method combines data from different sources, e.g., the health 
system and the criminal system. Each problem drug user is either in both samples or 
only in the health data base or only in the criminal data base or in none of the two data 
bases. The number of problem drug users found in the data bases can be arranged in 
a table as can be seen in table 3 below. Obviously, the number of those being in none 
of the two data bases cannot be observed and has to be estimated from the remaining 
cells of the table. Without making any restrictions any figure could be inserted in cell d. 
As this would not make sense one has to introduce a reasonable restriction.  This 
restriction is the assumption of independence: Being recorded in one system does not 
change the probability of being recorded in the other system. Or in more technical 
terms: The ratio of identified persons being in both samples to the total sample of the 
criminal system is assumed to be the same as the ratio of the sample of the health 
system  to  the  whole  population.  Then  the  extent  of  the  hidden  population  d  is 
estimated as d=b*c/a  with a, b, c as defined in table 3: 
Table 3: Example of the simplest form of a capture-recapture analysis 
    Sample 1   
    Present  Absent   
Sample 2  Present  A  b  a+b 
  Absent  C  d   
      a+c     
Accordingly,  the  total  number  of  problematic  drug  users  is  estimated  as 
N=a+b+c+(b*c/a). 
This method can also be embedded in the framework of loglinear models. These are 
models  for  the  analysis  of  contingency  tables.  In  the  case  of  a  two-way-table  the 
natural log of the content of a certain cell is modelled as the sum of a mean effect and 
the effect of the  row (e.g., being in the health data base) and the effect of the column 
(e.g. being not in the criminal data base) and the interaction effect between row and 
column. As in the capture-recapture situation the number of those being in none of the 
two data bases cannot be observed, the interaction effect cannot be estimated and has 
to be set to zero in advance. This corresponds with the independence assumption. 
In the framework of loglinear models the generalisation to more than two data bases is 
straightforward.  If  for  example  three  data  bases  are  employed  for  the  prevalence 
estimation, the corresponding table has seven known cells and one unknown. Then 
the  interaction  effect  for  the  three-way-interaction  in  the  loglinear  model  has  to  be 
omitted but two-way interactions are allowed. This means that dependencies between 
pairs  of  data  bases  can  be  handled.  Therefore,  in  most  cases,  at  least  three  data 
sources will be utilised, in order to account for possible relationships between data 
sources (see data demands and limitations).  
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Application 
Step 1  Collecting data of two (or better three) different data sources including 
exact identifiers able to determine the overlap between the samples. 
 
Step 2  Identifying the overlap 
 
Step 3  Conducting a log-linear analysis, as described in detail by Hay in the 
“Methodological guidelines to estimate the prevalence of problem drug 
use on the local level” (EMCDDA, 1998). In the case of two samples the 
loglinear analysis reduces to the formulas given in 5.5.1. 
 
 
Example: Sweden 
In 1992, an attempt was made to estimate the number of addicts in Sweden (Olsson, 
Byqvist & Gomer, 1994). Known addicts of 100 local communities were reported from 
sources  such  as  social  services,  hospitals  and  other  medical  units,  police,  prisons, 
probation  offices,  drug  treatment  units,  NGO’s  and  a  few  other  organisations.  The 
target population consisted of persons who illegally had used narcotic drugs during the 
last 12 months and who either injected drugs (regardless of frequency), or who used 
drugs by other ways of administration on a daily or almost daily basis. Application of 
the capture-recapture technique and an enumeration for the whole of Sweden gave an 
estimate of 17,000 heavy drug addicts.  
 
 
Data Demands 
Different aspects of drug use should be covered by the method (e.g., data of the legal 
system and the health system). Furthermore, if only two samples are employed the 
data  bases  have  to  be  mutually  independent,  i.e.,  the  probability  of  being  in  one 
sample must be independent of the probability of being in the other sample. A violation 
of  the  independence  assumption  can be handled by employing three or more data 
sources. This is the case, if the severity of the drug problem makes it more likely to 
seek help at an inpatient treatment facility. Then the appearance in the police data 
base is less likely. Other variables that may change the probability of being in one 
sample  can  be  the  socio-economic  status,  geographical  differences  or  the route of 
drug  administration.  In  general  terms:  the  examined  target  group  should  be 
homogenous and not contain hidden sub-groups. 
 
Great care has to be taken with coding exact identifiers for linking the data bases. 
These identifiers must be reliable and unambiguous; e.g., using only one initial, sex 
and date of birth may not be enough.  
 
On  a  more  general  level,  all  individuals  must  have  the  same  probability  of  being 
selected. This premise could not be met, if e.g. not all files would be available. The 
samples  should  be  representative  for  the  target  population  and  the  target  group 
definition should be equivalent for all data bases. 
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Limitations 
In the two sample case, positive dependence, i.e., being in one sample, increases the 
probability  of  being  in  the  other  sample,  leads  to  an  underestimate  of  the  hidden 
population,  negative  dependence  to  an  overestimate  (Domingo-Salvany  1997).  The 
capture-recapture approach can be derived from the framework of loglinear models. If 
there are more than two data sources available, fitting a loglinear model allows for 
accounting  for  dependence.  In  the  1997  local  estimation  project  this  method  was 
examined further by fitting several loglinear models to data from six European cities 
(EMCDDA 1997b). The properties of this method have been studied intensively on city 
levels. Not much is known yet about the extension to regions or nations. The problems 
are  manifold,  e.g.,  false  positives,  false  negatives,  double  counting,  identification 
problems of individuals. National estimates may be even more sensitive to the impact 
of these factors. 
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5.3.  Multivariate Indicator Method 
Statistical Background  
The Multivariate Indicator Method is a special case of synthetic estimation. Generally, 
synthetic estimation methods are methods which transfer information about a variable 
of interest, e.g. drug use prevalence, from a population in which it can be observed 
(calibration population) to a target population in which it cannot be observed (Rhodes, 
1993;  Wickens,  1993).  From  the  calibration  population,  a  functional  relationship 
between some variables and the variable of interest is derived which is extended to the 
target population. Applied to the field of drugs, the prevalence of problem drug use in a 
country may be estimated by relating a set of drug use indicators, which are available 
in  all  regions  of  a  country,  to  prevalence  estimates  in  a  few  regions  (calibration 
population).  The  indicators  may  be  directly  (e.g.  mortality,  morbidity,  arrest)  or 
indirectly  related  to  drug  use  (e.g.  population  density,  unemployment  rate,  housing 
density).  Typically,  analyses  are  based  on prevalence rates and indicator rates per 
100,000 inhabitants.  
 
With regard to the MIM, two main variants of the method are common. One way is to 
estimate the relationship between drug use indicators and prevalence estimates in the 
anchor points via (linear) regression and to apply the regression coefficients to the 
drug use indicators in the target population. This yields prevalence estimates for the 
non-anchor points. Summing up all regional prevalence estimates yields the national 
prevalence estimate. Smit and colleagues (2003) used this method to estimate local 
and national problem drug use prevalence in the Netherlands, employing population 
density  and  housing  density  as  indicators.  Apart  from  linear  regression  they  also 
employed non-linear regression models. The different regression models showed very 
similar  results.  In  the  US  Hser  and  colleagues  (1998)  related  the  prevalence  of 
poverty, unemployment, high school graduates and youths via logistic regression to 
the absolute numbers of drug using arrestees in several large and medium-size cities 
in order to estimate the prevalence of drug use among arrestees in 185 cities.  
 
In the second approach, (linear) regression is not applied to the indicators but to the  
principal  components  of  the  indicators.  Person  and  colleagues  (1977,  1978)  who 
introduced this method used the first principal component of the ranks of heroin use 
indicators and interpreted it as “heroin problem index” (HPI). They also proposed to 
create an HPI by summing up the ranks of the indicators. This approach was applied 
by Brugal and colleagues in their attempt to estimate the prevalence of addiction to 
opioids in Barcelona (Brugal et al., 1999). In recent years, MIM including PCA has 
been  applied  to  estimate  the  prevalence  of  problem  drug  use  on  national  level  in 
several European countries using drug-related indicators such as drug-related deaths, 
addicts in treatment or drug-related arrests (Frischer et al., 2001; Kraus et al., 2003). If 
indicators from different domains are included in the PCA one may get more than one 
latent  variable  which  may  be  interpreted  as  the  best  indicators  that  summarize the 
information provided by the indicators (Sartor & Walckiers, 2001). 
 
 
Application 
Step 1   Data  indicating  the  prevalence  of  drug  use  must  be  collected  for  a 
defined  time  period  for  each  region.  The  following  variables  are 
examples  for  indicators, but also other drug-related indicators can be 39 
used, e.g., seizure of controlled drugs. Not all available indicators may 
be the same for all countries. 
     
A  Number of drug-related offences (ideally person-based) 
B  Drug-related deaths 
C  Clients in treatment 
D  HIV cases related to IDU 
E  Imprisoned drug users 
     
Step 2   In addition, the population size F of the population at risk is needed. 
Most likely an age range will be introduced, e.g., the population at risk 
can be defined as the 15-54 year olds in 1995.  
 
Step 3  For  at  least  two  regions  reliable  independent  estimates  G  (maybe 
resulting from a capture-recapture study) are necessary. These regions 
are called „anchor points“. 
 
Step 4   For each of the variables A to E, G and for each region the figure per 
100,000 inhabitants has to be calculated.  
 
AF=A*100,000/F 
 
GF=G*100,000/F 
 
Step 5   Principal components analysis requires standardised values for AF to 
GF (subtracting the mean and dividing by the standard deviate). 
 
Step 6   Principal components analysis of AF to EF with the extraction of the first 
factor, whose coefficients are saved. No rotational solution is needed, as 
any  rotation  only  serves  as  an  improvement  for  the  fit  of  a  set  of 
indicators, and is therefore here redundant as only one indicator will be 
extracted. 
 
Step 7   A  linear  regression  (dependent  variable:  GF,  independent  variable: 
coefficients of the first factor) results in estimated prevalence rates per 
100,000 inhabitants. Finally, these have to be transformed to prevalence 
estimates for the regions (multiplying with F and dividing by 100,000). 
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Example: UK 
The example is taken from the UK country report on national prevalence estimates for 
the year 1999 (Frischer & Hickman, 1999). The relevant data have been assembled for 
the UK and are shown in table 4 as well as the results.  
 
As data for indicator E (emergency admissions) are only given for English regions this 
indicator was excluded from the analysis and calculations were based on the indicators 
A (convictions), B (seizures), C (treatments), D (cases of HIV related to IDU) as well as 
F (drug-related deaths).  
 
For Northern Ireland and for the regions of Wales only indicators A (convictions for 
drug offences) and B (seizures) were available. However, the other indicators were 
given for all of Wales. Therefore it was decided to enter all of Wales in the analysis 
and to estimate the prevalence of Great Britain in a first step and to extrapolate to all of 
the UK afterwards.  
 
As a prevalence estimate for all of Scotland was available also Scotland was taken as 
a whole in the analysis, increasing the proportion of anchor points from 35% to 50% (6 
anchor  points  out  of  17  regions  compared  to  5  anchor  points  out  of 10 regions, 8 
English regions + Wales + Scotland). 
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Table 4: UK data for the multiple indicator method 
Regions  Population  A  B  C  D  E  F  G  H 
England  47,055,204  83,553  92,075  51,850  788  11,711  2,371    215,574 
1.  Northern 
and 
Yorkshire 
6,600,626  11,356  13,285  9,722  37  1,989  344    35,095 
2.  Trent  4,606,495  6,451  7,010  3,580  67  395  207    14,574 
3.  Anglia and 
Oxford 
4,521,912  3,761  4,183  3,762  79  1,342  216    13,426 
4.  North 
Thames 
7,190,479  17,696  21,168  7,842  334  1,089  352  44,410  40,825 
5.  South 
Thames 
6,579,403  13,987  16,530  7,774  122  1,708  346  38,140  35,510 
6.  South West  6,131,705  10600  12,717  5,890  60  974  311    26,676 
7.  West 
Midlands 
5,150,246  7125  5,398  4,322  26  823  193  13,130  11,524 
8.  North West  6,274,338  12,557  11,804  8,958  63  3,391  402    37,944 
Wales  2,835,073  6,110  5,870  2,282  14    139  8,357  11,064 
1.  Dyfed 
Powys 
474,009  1,323  1,510             
2.  Gwent  452,650  1,262  1,044             
3.  North 
Wales 
658,790  1,315  1,218             
4.  South 
Wales 
1,331,086  2,210  2,098             
Scotland  5,120,000  3,008  13,452  8,614  687    267  38,000  39,307 
1.  Central  274,086  333  587  594  45    19     
2.  Dumfries 
and Galloway 
147,935  207  334  126  3    3     
3.  Fife  351,390  213  499  232  14    10     
4.  Grampian  532,770  673  1,393  829  12    31     
5.  Lothian and 
borders 
868,852  277  1,231  2,191  359    55  5,000   
6.  Northern  280,092  88  465  89  3    6     
7.  Strathclyde  2,283,671  943  7,989  4331  97    127  18,000   
8.  Tayside  395,309  274  954  222  154    16     
Northern 
Ireland 
1,600,000  772  1,291             
Total: Great  
Britain 
                265,945 
Total: UK  56,610,277  95,010  121,718  62,746          273,923 
A  Convictions for drug offences 
B  Seizures of controlled drugs  
C  People receiving treatment for drug misuse 
D  Cases of HIV related to IDU 
E  Emergency admissions for opioids 
F  Drug related deaths 
G  Estimated no of problematic drug users 
H  Model Estimate 42 
Data Demands 
Data requirements are firstly the availability of data on drug-related indicators broken-
down at a regional level, and secondly reliable prevalence estimates for at least two 
regions (anchor points).  
 
The same decomposition of regions, the same time period, the same data bases and 
the same definfitions (e.g. drug-related deaths defined as overdoses) should be used 
for  all  indicators.  If  the  data  bases  utilised  (e.g.,  health  system,  legal  system)  are 
based on different administrative regions it should be tried to merge or to split regions. 
Furthermore, data should be person-based and not event-based, that means that for 
example  the  number  of  drug-related  offenders  is  to  be  preferred  to  the  number  of 
convictions what may lead to problems with privacy regulations. The indicators should 
refer  to  the  age  group  that  is  employed  in  calculating  the  figures  per  100,000 
inhabitants. 
 
As the anchor points have a great impact on the actual figures of the total prevalence 
by fixing the regression line, great care has to be taken in obtaining reliable and valid 
estimates with the same target group. Furthermore, the estimates should cover at least 
one area with an assumed high prevalence rate and at least one region at the lower 
end of prevalence rates, in order to improve the quality of the regression model. Using 
only estimates of regions with a high prevalence makes the method useless, and may 
even result in negative prevalence rates. Indicator values for the anchor points must be 
available.  In  practice,  prevalence  estimates  are  often  available  only  on  city  level 
whereas  indicators  are  collected  on  a  regional  level.  If  problem  drug  use  is 
concentrated heavily in these cities they may be used as anchor points.  Otherwise, 
the surrounding region should be split in the anchor point and the region without the 
anchor  point  and  indicator  values  must  be  collected  for  both  sub-regions.  Note, 
however, that the relationship between indicators and drug use prevalence may be 
different for metropolitan and rural areas.   
 
 
Properties of the method 
A  project  funded  by  the  European  Community  under  the  Targeted  Socio-Economic 
Research  (TSER)  aimed  at  the  exploration  of  the  properties  of  the  multivariate 
indicator method (EMCDDA, 2002). One of the main results was, that the method is 
relatively  robust  towards  some  systematic  biases  of  the  indicators,  i.e.  the  use  of 
event-based data instead of person-based data in some or all regions, the inclusion of 
previous drug users or report not by area of residence. Also the age-group has only a 
negligible impact on the prevalence estimates. The choice of the anchor point turned 
out to be crucial for the method but also the selection of indicators had an impact on 
the outcome. It was concluded that the method is appropriate for national, but not for 
regional  prevalence  estimation.  The  choices  of  different  sets  of  anchor  points  or 
indicators seem to effect the regional prevalence rates more than the national ones. 
Sensitivity analyses and cross-validation with capture-recapture estimates showed that 
changes of anchor points or indicators lead to high variations of the regional estimates, 
although the national estimates remained rather similar. 
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Summary and Overview 
 
The definition of the target group is closely linked to the availability of data. 
 
With data bases identifying 
a)  the  main  drug  consumed  (e.g.,  polydrug  use  including  opiates,  monodrug  use  of 
opiates, monodrug use of cocaine), 
b)  the  severity  of  the  drug  problem  (e.g.,  dependence,  abuse,  non-problematic  use 
according to ICD or DSM criteria), 
c)  route of administration (e.g., inhaling, injecting, oral) 
on an individual base all possible target groups can be estimated. 
 
The validity of the estimate is dependent on  
a)  Definition of target group and thus quality of data sources 
b)  Quality  of  independent  measurements  like  anchor  points  (Multivariate  indicator 
method) or multipliers 
 
An operational definition of a comparable target group is  
a)  Intravenous  drug  use  (IDU)  or  long  duration/regular  use  of  opiates,  cocaine  or 
amphetamines,  
b)  During a one-year period,  
c)  In the age group 15-64. 
 
 
Multiplier method using treatment data  
a)  Is there a treatment monitoring system of which the number of all registered drug 
users can be obtained for the specific target group? 
b)  Does it cover all possible treatment centres or can a coverage rate be obtained? 
c)  Is there a reasonable estimate for the in-treatment-rate for the specific target group? 
 
Multiplier method using police data and the ratio of all drug-related deaths to those deceased 
previously been known as drug users 
a)  Can the police data base of registered drug users be utilised for the specific target 
group? 
b)  Are there ways of linking it to the data base of drug-related deaths? 
c)  On which definition is the register of drug-related deaths based? 
d)  Has the target group to be modified to fit to the second data base? 
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Multiplier method using police data 
a)  Can the police data base of registered drug users be utilised for the specific target 
group? 
b)  Is  there  a  reasonable  estimate  for  the  proportion  of  drug  users having come into 
contact with the police for the specific target group? 
 
Multiplier method using mortality data 
a)  On which definition is the register of drug-related deaths based? Does it contain all-
cause deaths? 
b)  Does it fit to the definition of the target group? 
c)  Is there a reasonable estimate for the mortality rate for the specific target group? 
 
Multiplier method using HIV/AIDS data 
a)  This method has a clearly defined target group: prevalence of life-time intravenous 
drug use. 
b)  The method is not advisable for countries with a small AIDS epidemic among the 
general population and the intravenous drug users. 
 
Capture-recapture method 
a)  Are different aspects of drug use covered? 
b)  Is the target group homogenous? 
c)  Are the target group definitions equivalent in all samples? 
d)  Is the identifier unambiguous? 
 
Multivariate indicator method 
a)  Data demands are quite high: A variety of drug-related indicators on a regional basis 
is needed that should reflect the assumed target group. 
b)  At least two already existing estimates for regions at the lower and higher end of 
prevalence are necessary. 
c)  The target group is determined by the target group of the anchor point estimates. 
 
Additional small scale studies can help to increase the quality of the described methods. 
Studies on the duration of drug use in different countries of the EU as well as the coverage 
of the drug using population by treatment services could reduce uncertainties concerning the 
multipliers used. 
The  age  range  15-64  is  perceived  as  a  useful  reference  frame  for  the  calculation  of 
prevalence rates.  
Regarding  comparisons  of  results  of  different  methods  one  should  be  aware  of  the 
respective  target  groups.  As  the  back  calculation  method  estimates  IDU,  for  example, 
prevalence whereas extrapolation from police data is supposed to include also low-frequent 
user  and  non-IDUs,  the  police  multiplier  estimate  should  exceed  the  back  calculation 
estimate.  In  practice,  however,  it  is  possible  that  the  estimate  from  the  back  calculation 
method is higher than the police multiplier estimate. This may result from a comparatively 47 
high proportion of AIDS affected or HIV infected having already exited the IDU population, 
from  invalid  multipliers  or  denominators  in  at  least  one  of  the  methods,  or  simply  from 
random errors.  
Moreover,  one  should  always  be  aware  of weaknesses of the data. Multipliers based on 
small-scale  studies  may  not  be  valid  nationwide  or  certain  subgroups  may  be  over-
represented in data files. For instance, it is supposed that in the German statistics on drug-
related deaths IDUs are over-represented and non-IDUs that died at a fatal accident under 
the influence of illicit drugs are under-represented as those are less likely to be recognised 
as drug users. 
At present, a recommendation for a certain method – given availability of all data bases – 
can  not  be  given.  The  performance  of  the  more  elaborated  methods  –  the  multivariate 
indicator method and the capture-recapture method on a national level – is not investigated 
in detail up to now. Both methods seem to have in common that in spite of a reasonable 
national  estimate  regional  estimates  or  estimates  for  subpopulations  might  be  rather 
implausible  (Rossi,  meeting  of  the  participants  of  the  EMCDDA  project  "Study  to  obtain 
comparable national estimates of problem drug use prevalence for all EU member states” in 
Munich in April 1998; Uhl, IV EASAR congress in Rome, May 22-24, 1998). On the other 
hand  side  both  methods  seem  to  be  promising  because  of  their  ability  to  combine 
information from different sources. The properties of the multivariate indicator method are 
studied  in  the  EMCDDA  project  “Targeted  Socioeconomic  Research”.  One  should  be 
cautious if multipliers or denominators are rather small or rather big as small changes in the 
multiplier/denominator have an enormous impact on the prevalence estimates. This applies 
specifically to the back calculation and the mortality multiplier method. For the extrapolation 
from  treatment  data,  the  police  multiplier  method  as  well  as  the  police/death  multiplier 
method very small or very big multipliers have not been observed so far.  